ELV CLASS ACTION: A Securities Fraud Lawsuit was filed on behalf of Elevance Health, Inc. Investors -- Contact BFA Law by July 11 Deadline (NYSE:ELV)

Then, on October 17, 2024, Elevance announced its Q3 2024 financial results, revealing that its missed consensus earnings per share ("EPS") expectations by $1.33, or 13.7%, "due to elevated medical costs in [its] Medicaid business." On this news, the price of Elevance stock declined$ 52.61 per share, or nearly 11%, from $496.96 per share on October 16, 2024, to$ 444.35 per share on October 17, 2024. NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces t ...